Insud Pharma
Kreis German is an experienced medical professional specializing in clinical pharmacology and patient safety. Currently serving as the Patient Safety Physician and Risk Mitigation Manager at Insud Pharma since February 2022, Kreis previously held multiple roles at Almirall, including QPPV Deputy at Corporate Drug Safety and Safety and Pharmacovigilance Physician from January 2013 to January 2022. Kreis's early career included positions at Hospital Clínic de Barcelona as a Physician MD, PhD and member of the Medical Staff of Medicines Safety and Efficacy Evaluation Unit, alongside serving as a Clinical Pharmacologist during residency at Vall d'Hebron Barcelona Hospital Campus. Additional training includes a General Surgery Residency at Hospital J R Vidal, highlighting a comprehensive background in both clinical and surgical disciplines.
Insud Pharma
5 followers
INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.